MeSH D012751 - sezary syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Horizon Therapeutics Public | Interferon gamma-1b | Actimmune | 1999-02-25 | $122.816 M | Q3/22-Q2/23 | |
| Kyowa Kirin | Mogamulizumab | Poteligeo | 2018-08-08 |
Clinical Trials
Historical Success Rate
Phase 1
56%18/32
Phase 2
0%0/25
Phase 3
80%8/10
Approved: 8Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use